Analysis on off-label use of drugs in pediatric guidelines and consensus published by Chinese authors

Objective: To understand the current situation regarding pediatric off-label use of drugs recommendations in Chinese clinical practice guidelines and to make recommendations for standardized reporting format regarding off-label use of drugs for children. Methods: This cross-sectional study was carri...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 60(2022), 3 vom: 02. März, Seite 215-220
1. Verfasser: Meng, M (VerfasserIn)
Weitere Verfasser: Wang, P, Lan, H, Lei, W J, Shen, Q, Zhou, Q, Su, R F, Lyu, M, Yang, B, Luo, X F, Lei, R B, Hou, T C, Li, Q, Chen, Yaolong
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:Journal Article Pharmaceutical Preparations
LEADER 01000naa a22002652 4500
001 NLM337719500
003 DE-627
005 20231225235045.0
007 cr uuu---uuuuu
008 231225s2022 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20210923-00813  |2 doi 
028 5 2 |a pubmed24n1125.xml 
035 |a (DE-627)NLM337719500 
035 |a (NLM)35240741 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Meng, M  |e verfasserin  |4 aut 
245 1 0 |a Analysis on off-label use of drugs in pediatric guidelines and consensus published by Chinese authors 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 07.03.2022 
500 |a Date Revised 07.03.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To understand the current situation regarding pediatric off-label use of drugs recommendations in Chinese clinical practice guidelines and to make recommendations for standardized reporting format regarding off-label use of drugs for children. Methods: This cross-sectional study was carried out by systematically searching the databases for Chinese guideline consensus articles published in journals between 2018 and 2020 and extracting recommendations regarding off-label use of drugs from those articles. The essential characteristics of the included guidelines, the ranking of off-label drug types, the order of drug information, the type of off-label drug use, and the percentage of citation studies on which the recommendations were based were analyzed. Results: Among 108 studies that included Chinese off-label guidelines and consensus, 364 recommendations on pediatric off-label use of drugs were included. The Chinese Medical Association published the most, 48 out of the 108 studies (44.4%), and of those 14 studies (13.0%) were on infectious and parasitic diseases. Of the 364 recommendations on off-label use of drugs, the most commonly addressed drugs were 16 recommendations (4.4%) for cyclosporine A, 11 recommendations (3.0%) for methotrexate , and 11 recommendations (3.0%) for fentanyl. The most commonly addressed drug categories were as follows: 68 recommendations (18.6%) were immune system drugs, 66 recommendations (18.1%) were anti-infectives, and 56 recommendations (15.4%) were oncology drugs. The most commonly addressed drug information accounts were as follows: 364 recommendations (100.0%) were indications, 204 recommendations (56.0%) were dosages, and 198 recommendations (54.4%) were the route of administration. Based on the instructions approved by the Chinese Food and Drug Administration, the main forms of the off-label drug were as follows: 175 recommendations (48.1%) were unapproved indications, 127 recommendations (34.9%) were unapproved populations, and 72 recommendations (19.8%) were unapproved ages. Only 129 recommendations (35.4%) were cited, mainly including clinical guidelines (48 studies, 23.4%), reviews (22 studies, 10.7%), and pediatric randomized controlled trials (22 studies, 10.7%). Conclusions: Off-label use of drugs is commonly recommended in pediatric guidelines and consensus documents written by Chinese authors. However, the reporting of the recommendations varies widely, and the quality of the supporting evidence is poor 
650 4 |a Journal Article 
650 7 |a Pharmaceutical Preparations  |2 NLM 
700 1 |a Wang, P  |e verfasserin  |4 aut 
700 1 |a Lan, H  |e verfasserin  |4 aut 
700 1 |a Lei, W J  |e verfasserin  |4 aut 
700 1 |a Shen, Q  |e verfasserin  |4 aut 
700 1 |a Zhou, Q  |e verfasserin  |4 aut 
700 1 |a Su, R F  |e verfasserin  |4 aut 
700 1 |a Lyu, M  |e verfasserin  |4 aut 
700 1 |a Yang, B  |e verfasserin  |4 aut 
700 1 |a Luo, X F  |e verfasserin  |4 aut 
700 1 |a Lei, R B  |e verfasserin  |4 aut 
700 1 |a Hou, T C  |e verfasserin  |4 aut 
700 1 |a Li, Q  |e verfasserin  |4 aut 
700 1 |a Chen, Yaolong  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 60(2022), 3 vom: 02. März, Seite 215-220  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:60  |g year:2022  |g number:3  |g day:02  |g month:03  |g pages:215-220 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20210923-00813  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 60  |j 2022  |e 3  |b 02  |c 03  |h 215-220